Nkarta focuses on the development of natural killer (NK) cell therapies for the treatment of cancer and autoimmune diseases, utilizing proprietary technology for NK cell expansion.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

COM:NKARTATX

Nkarta, Inc.

Last Close

3.05

13/11 21:00

Market Cap

386.16M

Beta: -

Volume Today

695.83K

Avg: -

locale

market

industry

website

crunchbase

ipo date

peer of

Metrics